Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MYC | P01106 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30466426 | 1.00 | MAPT (0.68) | MAPTTDP1SMN1; SMN2MAPK1LMNA | |
| SCHEMBL732725 | 0.88 | MAPT (0.61) | MAPTTDP1SMN1; SMN2MAPK1LMNA | |
| SCHEMBL10740410 | 0.85 | LMNA (0.56) | MAPTTDP1SMN1; SMN2MAPK1LMNA | |
| SCHEMBL4309406 | 0.85 | MAPT (0.62) | MAPTTDP1SMN1; SMN2MAPK1LMNA | |
| SCHEMBL102827 | 0.84 | MAPT (0.72) | MAPTTDP1ALDH1A1MYCCDC25B | |
| SCHEMBL24136599 | 0.83 | LMNA (0.55) | MAPTTDP1SMN1; SMN2MAPK1LMNA | |
| SCHEMBL30466421 | 0.83 | LMNA (0.55) | MAPTTDP1SMN1; SMN2MAPK1LMNA | |
| Hydrochloric Acid SCHEMBL5061862 | 0.82 | MAPT (0.70) | MAPTTDP1ALDH1A1MYCCDC25B | |
| Water SCHEMBL9749470 | 0.82 | MAPT (0.70) | MAPTTDP1ALDH1A1MYCCDC25B | |
| SCHEMBL11218412 | 0.82 | TDP1 (0.50) | MAPTTDP1SMN1; SMN2MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100475805-C | Method for synthesizing 3-methyl-7-,8-dihydroxyisochromanone-4 | UNIV CHINA PHARMA (CN) | 2009-04-08 | — | — | CN | claimed |
| US-12344618-B2 | Heterotricyclic derivative compound and use of same | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2025-07-01 | — | — | US | disclosed |
| CN-116194108-B | Novel dioxoisoquinolinone derivatives and use thereof | 韩美药品株式会社 | 2025-05-30 | — | — | CN | disclosed |
| EP-4556479-A1 | NOVEL DIOXOLOISOQUINOLINONE DERIVATIVES AND USE THEREOF | Hanmi Pharmaceutical Co., Ltd. (KR) | 2025-05-21 | — | — | EP | disclosed |
| CN-113423710-B | Novel heterocyclic tricyclic derivative compounds and use thereof | 韩美药品株式会社 | 2024-06-14 | — | — | CN | disclosed |
| EP-3201251-B1 | NEW PHENOLIC POLYMERS AND PREPARATION PROCESSES THEREOF | UNIV BORDEAUX (FR) | 2024-04-24 | — | — | EP | disclosed |
| EP-4196483-A1 | NOVEL DIOXOLOISOQUINOLINONE DERIVATIVES AND USE THEREOF | Hanmi Pharmaceutical Co., Ltd. (KR) | 2023-06-21 | — | — | EP | disclosed |
| CN-116194108-A | Novel dioxoisoquinolinone derivatives and use thereof | 韩美药品株式会社 | 2023-05-30 | — | — | CN | disclosed |
| US-11535629-B2 | Dioxoloisoquinolinone derivatives and use thereof | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2022-12-27 | — | — | US | disclosed |
| US-11535629-B2 | Dioxoloisoquinolinone derivatives and use thereof | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2022-12-27 | — | — | US | disclosed |
| US-5824688-A | HIV protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 1998-10-20 | — | — | US | disclosed |
| EP-0722439-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-07-24 | — | — | EP | disclosed |
| US-5484926-A | VIRICIDES AND ENZYME INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-01-16 | — | — | US | disclosed |
| WO-1995009843-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-04-13 | — | — | WO | disclosed |
| EP-0292202-B1 | 2-(3,4-DIHYDROXYPHENYL ETHYL AMINES, THEIR PREPARATION AND USE AS PHARMACEUTICAL COMPOUNDS | FISONS plc (GB) | 1992-09-02 | — | — | EP | disclosed |
| US-4939147-A | Substituted 3,4-dihydroxy phenylethylamino compounds | FISONS PLC. (GB) | 1990-07-03 | — | — | US | disclosed |
| US-4922022-A | Substituted 3,4-dihydroxy phenylethylamino compounds | FISONS PLC (GB) | 1990-05-01 | — | — | US | disclosed |
| EP-0314725-A1 | 2-(3,4-DIHYDROXYPHENYL)ETHYLAMINES, THEIR PREPARATION AND USE AS PHARMACEUTICAL | FISONS plc (GB) | 1989-05-10 | — | — | EP | disclosed |
| WO-1988009326-A1 | 2-(3,4-DIHYDROXYPHENYL)ETHYLAMINES, THEIR PREPARATION AND USE AS PHARMACEUTICAL | FISONS PLC (GB) | 1988-12-01 | — | — | WO | disclosed |
| EP-0292202-A1 | 2-(3,4-Dihydroxyphenyl ethyl amines, their preparation and use as pharmaceutical compounds | FISONS plc (GB) | 1988-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535629-B2 | Dioxoloisoquinolinone derivatives and use thereof | EZH2, EZH1, EED | MAPT 1430/4885TDP1 2942/4885SMN1; SMN2 2875/4885 |
| US-12344618-B2 | Heterotricyclic derivative compound and use of same | EZH2, EZH1, BMI1 | MAPT 4373/4885TDP1 4524/4885SMN1; SMN2 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.